Exploring the remyelinating efficacy of nanoliposomes encapsulating and in a murine model of induced demyelination.

Demyelination leads to neuropathies and clinical deficits. Chemical remyelinating agents have variable efficacy and severe undesirable effects. Withania somnifera and are traditionally known for possessing neuroprotective effects. The present study endeavors to reverse the demyelination using root extract () and leaf extract () liposomes prepared using thin-film hydration. The mean particle size (89.7 nm for , 85.5 nm for ), zeta potential (-0.21 mV for , +0.455 mV for ), and encapsulation efficiency (98.7% for , 97.5% for ) were recorded. FTIR analysis indicated similar absorption peaks between the crude extracts and nano-liposomal formulations, with slight shifts observed. Scanning electron microscopy confirmed smooth, spherical structures. To evaluate the therapeutic efficacy of oral gavage of and in a cuprizone-induced demyelinated mice model, they were randomly divided into groups, namely Control (Healthy, Sham and Vehicle), (low and high dose), (low and high dose), crude extract (low and high dose) and Prednisolone. Treatment efficacy was assessed using behavioral tests (SHIRPA, Rota-rod, Hot-plate, NORT, and EPM), hematobiochemical, histology, and immunohistochemical analyses. The in high doses had significant improvement compared to others, highlighting its potential as a promising therapy for demyelinating neuropathies, paving the way for advancements in neurobiomedical science.